Trade name
Ondansetron (Accord), Ondansetron (AFT), Ondansetron Kabi, Ondansetron-Baxter, Ondansetron Viatris
Strength
2 mg/mL (volume: 2 mL, 4 mL)
IV administration
Give undiluted over 2 – 5 minutes, or dilute to 1 mg/mL or weaker and infuse over 15 minutes.
Other routes of administration
IM: Suitable. Administer as undiluted injection.
SC: Not recommended. May be given as an intermittent or continuous SC infusion in palliative care settings.
Compatible IV fluids
Glucose 5%
Glucose 5% and sodium chloride 0.9%
Ringer’s
Hartmann's
Sodium chloride 0.9%
Y-site only:
Potassium chloride 20 mmol/L
Y-site only and ondansetron 1 mg/mL or weaker:
Plasma-Lyte 148
Additional information
Rapid administration is associated with a higher incidence of transient visual disturbances.
Use with caution in patients pre-disposed to QT interval prolongation or in patients being administered other medications known to prolong QT interval.
Protect from light during storage.